Showing 521 - 540 results of 105,819 for search '(( 2 fold decrease ) OR ( 5 ((we decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.63s Refine Results
  1. 521

    Structure of YOLOv5s-SBC. by Zhongjian Xie (4633099)

    Published 2024
    “…Compared to the original model, P-YOLOv5s-GRNF decreased parameters by 18%, decreased model size to 11.9MB, decreased FLOPs to 14.5G, and increased FPS by 4.3. …”
  2. 522
  3. 523
  4. 524
  5. 525
  6. 526
  7. 527

    A summary of the included study characteristics. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  8. 528
  9. 529
  10. 530
  11. 531
  12. 532
  13. 533

    MMR mutants show decreased mating-type silencing. by Qian Liu (135614)

    Published 2020
    “…Cells were five-fold serially diluted and then spotted onto SD-ura-leu + 2% glucose (left) or SD-ura-leu + 2% galactose (right) agar plates. …”
  14. 534
  15. 535

    Beta-catenin signaling is decreased in intermediate progenitor cells. by Christopher A. Mutch (243132)

    Published 2010
    “…<p>(<b>A</b>) Cortex from E14.5 Axin2-d2EGFP transgenic mice stained for GFP (green), Tbr2 (red), and DNA (blue). …”
  16. 536
  17. 537
  18. 538
  19. 539

    Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease by Sandra L. Dabora (206838)

    Published 2011
    “…Kidney angiomyolipomas regrew when sirolimus was discontinued but responses tended to persist if treatment was continued after week 52. We observed regression of brain tumors (SEGAs) in 7/11 cases (26% mean decrease in diameter), regression of liver angiomyolipomas in 4/5 cases (32.1% mean decrease in longest diameter), subjective improvement in facial angiofibromas in 57%, and stable lung function in women with TSC/LAM (n = 15). …”
  20. 540

    Administration of APB5, but not APA5, decreases the hyperplasia of alveolar type 2 epithelial cells induced by BLM. by Masami Kishi (6167105)

    Published 2018
    “…The administration of APB5 markedly decreased the hyperplasia of type 2 epithelial cells induced by BLM. …”